Cilia Restoration Compositions Targeting Disassembly Pathways

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a limited understanding of the mechanisms regulating cilia disassembly and their role in diseases such as focal cortical dysplasia (FCD), and existing treatments have not effectively targeted cilia restoration to mitigate these disorders.

Innovation Solution

Administering inhibitors of proteins involved in cilia disassembly, including F2R, SARM1, RyR1, RyR2, RyR3, RhoA, and ROCK1/2, along with LPAR1, mTORC1, and Ca2+ chelators, to inhibit cilia disassembly and promote restoration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If inhibitors of cilia disassembly proteins are administered, then ciliary function is restored, but the complexity of treatment increases

Engineering Contradiction:

Improveciliary function restorationVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The treatment targets specific proteins in the cilia disassembly pathway (F2R, SARM1, RyR1, RyR2, RyR3, RhoA, ROCK1/2) with dedicated inhibitors, segmenting the complex biological process into discrete targetable steps. This allows selective intervention at multiple points in the disassembly cascade.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses small molecule inhibitors as intermediary substances that bind to and block the activity of disassembly proteins. These intermediaries translate the therapeutic intent into specific molecular interactions that prevent cilia disassembly without directly modifying the cilia structure.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If multiple protein inhibitors are used to restore cilia, then treatment effectiveness improves, but the number of components increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidnumber of inhibitor components

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent combines multiple inhibitor treatments into a coordinated therapeutic regimen. By simultaneously or sequentially administering inhibitors against different proteins in the disassembly pathway, the treatment merges multiple molecular interventions into a unified therapeutic strategy that addresses the cascade nature of cilia disassembly.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The treatment approach is designed to be universally applicable across different ciliopathy contexts by targeting conserved proteins in the cilia disassembly pathway. The same inhibitor strategy can address various underlying causes (F2R mutations, SARM1 activation, RyR dysfunction, RhoA/ROCK signaling) through a common mechanistic approach.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20260053804A1Compositions and Methods for the Restoration of Ciliary Function

Publication Date: 2026.02.26 YALE UNIVERSITY

AI summary

Provided are compositions and methods for preventing cilia degeneration and treating diseases and disorders associated therewith.